TMB and Neoantigen Congress

When

2019年10月10-11日
Registration from 8am

Where

英国,伦敦
London Heathrow Marriott Hotel

TMB and Neoantigen Congress
-TMB、新生抗原学会-
日期:2019年10月10-11日
地点:英国,伦敦,London Heathrow Marriott Hotel
Choose your language
Chinese
Japanese
Korean
English

TMB and Neoantigen Congress

在新标的、预测生物标记、个别化医疗领域的进步

此学会透过预测生物标记以及新生抗原的创新研究,聚焦于以下课题:研究者致力于如何将成功可能性高的疗法与患者连结。在会议期间,也包括关于肿瘤突变负荷量(TMB)的最新研究,在免疫疗法药物的治疗效果确认使用TMB的可能性、关于其他预测生物标记之开发等主题之会议,还有探讨新生抗原成为精密医疗新标的可能性之会议。

“I met leading companies/biomarker developers at one place sharing cutting edge technologies”.

“interesting mixture of topics; possibility to discuss with the attendees”

“Learned a lot from some of the talks”

此学会是关于癌症免疫疗法的研究及技术为主题的系列活动之一。申请参加此学会的来场者,能够在5个学会中聆听100个以上的演讲,还能够与跨领域的人们认识,扩大人脉,吸收新知。

可参加同时举办的学会

 

2019年10月10日(四) – 关于TMB与新生抗原研究之运用


基调演讲: 癌症免疫疗法药物开发的ctDNA生物标记:可能性及课题
RAJIV RAJA, Director, Oncology Translational Medicine, AstraZeneca, USA
Circulating tumor DNA (ctDNA) derived from plasma offer significant promise as a tool for assessing tumor burden and antitumor response. Changes in levels of ctDNA from baseline have been shown to correlate with response to some immunotherapies. Recent studies have also shown that ctDNA could be used to measure tumor mutation burden (TMB) which could be a potential predictive biomarker for response to immunotherapies. ctDNA results from immunotherapy studies will be discussed, and opportunities and challenges with ctDNA analysis will be discussed.

基调演讲: 减轻毒性风险&对患者的利益最大化
CHRISTOPHE LE TOURNEAU, Head, Department of Drug Development and Innovation (D3i), Institut Curie, France
Optimising patients benefit whilst reducing toxicity risk is the ultimate goal of precision medicine in oncology. While precision medicine has always been a reality in medicine with treatments adjusted based on the clinical condition of patients, the term “precision medicine” has arisen with the advent of molecularly targeted therapies that were developed based on biomarkers that were mostly DNA alterations. Precision medicine does not apply only for molecularly targeted therapies but also for immunotherapeutics especially immune checkpoint inhibitors, for which predictive biomarkers of efficacy have been identified at the genomic level.

PRESENTATION


Morning Refreshments / Poster Presentations


Will whole genome sequencing of fresh frozen tumour material become the assay of choice for cancer molecular diagnostics?
WILL SPOONER, Commercial Programme Delivery Lead, Genomics England, UK
At the start of the 100,000 Genomes Project it became clear that formalin fixed paraffin embedded tumour material was not suitable for whole genome sequencing. An alternative “WGS friendly” fresh frozen protocol (FF-WGS) was developed and implemented as a clinical pathway in the NHS. This protocol has been used to generate a dataset of linked genome-to-health data from 15,000 cancer cases. Analysis of the dataset suggests that our FF-WGS assay that has the potential to more reliably and accurately measure cancer markers such as TMB. This talk presents these data and considers the challenges of introducing FF-WGS-based tests into clinical
trials and practice. Finally, we speculate on the mining of large FF-WGS datasets to identify the next generation of cancer biomarkers.

TMB and MSI in clinical application using comprehensive tumor profiling
MARTIN ZOCHE, Director Molecular Tumor Profiling, University Hospital Zurich, Switzerland
• Comprehensive molecular tumor profiling is standard at the University Hospital Zurich is as a diagnostic standard
procedure for all tumor patients.
• Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) analysis are integrated in the molecular report
and discussed.
• Patient cases will illustrate the advantages for the tumor patients

PRESENTATION
Oncoimmunity


Lunch


ATLAS™ - A Critical Tool in Finding True Neoantigens
PAMELA CARROLL, Senior Vice President, Scientific Strategy, Genocea Biosciences, USA
• ATLAS™ is a powerful tool that screens all candidate neoantigens for pre-existing patient-specific CD4 or CD8 responses
in an HLA agnostic assessment.
• ATLAS also identifies inhibitory peptides that may suppress tumor immunity, accelerate tumor progression and mediate
patient response to immune checkpoint blockade therapies.
• ATLAS-selected neoantigens are the basis of a vaccine, GEN-009, currently being evaluated in Phase 1/2a clinical trials. Also, ATLAS is
being applied to a personalized non-engineered T cell therapy program that targets multiple neoantigens.

Combined treatment with checkpoint blockade and Adenovirus vaccine targeting multiple neoantigens eradicates large tumors in mice
ELISA SCARSELLI, CSO, Nouscom, Italy
• Non-human Great Ape Adenoviruses (GAd) are potent vaccine vectors able to encode many neoantigens
• Vaccination synergizes with α-PD-1 in mice bearing large established tumours
• Combined treatment results in diversification of the intra-tumor T cell repertoire

Considerations and experiences from taking a fully personalized targeted cancer neoantigen DNA vaccine into the clinic
AGNETE FREDRIKSEN, President and CSO, Vaccibody, Norway
• What is the rationale to pursue development of individualized cancer vaccines and make it a viable product for the market?
• How does the vaccine format affect the immunogenicity profile of individual neoepitopes?
• Update from DIRECT-01, a clinical trial testing private cancer neoantigen based vaccines in patients with advanced cancer


Afternoon Refreshments / Poster Presentations


Tailor-made immunotherapies: Integrating non-mutated and neoantigens into highly personalized
immunotherapy approaches
SARAH MISSEL, Director, Translational Development, R&D Strategy and Communications, Immatics, Germany
• The role of neoantigens and non-mutated antigens in tumors with low mutational burden
• GAPVAC – Actively Personalized Vaccination in newly diagnosed glioblastoma patients – results of the clinical study
GAPVAC-101
• Highly personalized Adoptive Cellular Therapy

Viral-based vaccine for cancer neoantigen vaccination
KAIDRE BENDJAMA, Project Leader, Personalized Cancer Vaccination, Transgene, France
Viral vectors constitute a promising modality for cancer vaccines. Viral vectors were used successfully to generate cancer vaccines in a number of indications using Tumor associated antigen as targets to induce a specific T cell response. The presentation will provide an overview on how Transgene uses the MVA viral strain to meet specific challenges related neoantigen vaccination from sequencing to neoepitope selection to manufacturing and QC to deliver a clinical grade product and on how these vaccines will be translated into the clinic in indications of high medical needs.


Networking Drinks Reception


染色体碎裂(Chromothripsis)有可能提高新生抗原负荷
GEORGE VASMATZIS, Co-director of the Biomarker Discovery Program, Associate Professor, Department of Molecular Medicine, Mayo Clinic, USA
• We observed that inter- or intrachromosomal rearrangements are present in many cancers frequently in a pattern of chromoanagenesis such as chromoplexy or chromothripsis.
• Transcription of rearrangement-related junctions was predicted to result in many potential neoantigens, some of which were proven to bind patient-specific major histocompatibility complex molecules and to expand intratumoral T cell clones.
• Subsets of prostate, lung, and breast, cancers as well as some sarcomas are among those that could present neoantigens that derive from complex rearrangements

PepPipe - an immunomics workflow elucidating antigenic peptide biomarker signatures for minimal invasive diagnostics
ANDREAS WEINHAUSEL, Thematic Coordinator, Molecular Diagnostics, AIT - Austrian Institute of Technology, Austria
Autoantibody & antibody-profiles are biologically meaningful and suitable as early and minimal invasive markers using 10µl of plasma or serum. Since the immune system plays a major role in many diseases, sero-testing and immunomics analysis has a broad area of application and a high potential for diagnostics of autoimmune, cancerous, cardiologic, neurodegenerative and systemic diseases, as well as assisting biotech and pharma for selecting therapeutic targets or study off-target reactivities. PepPipe provides an entire workflow of optimised and QM qualified methods to define antigenic proteins and peptides for
serological analysis. We have developed a broad variety of assays with different multiplexing capacities to provide the entire workflow “from screening to validation” and “from proteins to peptides” to define and analyse antigenic proteins and peptides supporting clinical and therapeutic developments, and improving robust minimal invasive diagnostics.


Morning Refreshments / Poster Presentations


The promise and challenge of TMB in the clinics for immunotherapy
EUN-ANG RAIBER-MOREAU, Associate Principal Scientist, AstraZeneca, UK
Tumour mutational burden (TMB) is emerging as an important biomarker that hold promise to aid in the selection of patients for immunotherapy. TMB is defined as the total number of mutations per megabase within the coding area of the genome. TMB was initially assessed using whole exome sequencing but new studies have shown that targeted NGS panels can be used for TMB calling reducing down the costs and turn-around time. In this presentation, we will discuss the challenges of implementing TMB testing into routine clinical settings with a focus on the importance of TMB standardization and blood versus tissue TMB testing

Developing proteogenomcis platforms in cancers of high unmet clinical need
TEDD HUPP, Chair of Cancer Research, University of Edinburgh, UK
Proteogenomics platforms are being developed that can reveal the expressed cancer genome as we evolve towards personalized therapies. Our network aims to (i) define comprehensively the biological sources of cancer neoantigens; (ii) evolve algorithmic strategies for mass-spectrometry based mutation identification; (iii) identify novel genes that regulate MHC Class I production in cancers; and (vi) apply this knowledge on the mutant peptidome to form therapeutic options in cancers of high unmet clinical need.


Lunch


Using Artificial Intelligence to accelerate Immunotherapy
JENS KRINGELUM, Director, Genomic Immuno Oncology, Evaxion Biotech, Denmark
• What is AI and how can it be used to predict immune responses in patients
• The use of AI driven prediction tools for design of novel immunotherapies
• Opportunities and challenges in using AI technology to drive truly personalised treatments

Application of in vitro tools that improve selection of (neo)epitopes and characterize T cell responses
ASTRID VISSER, Business Development Manager, Sanquin, The Netherlands
• Measured peptide-MHC binding / stability that improves (neo)epitope selection
• Multi-parameter FACS that efficiently detects and characterizes multiple pre-existing and induced epitope-specific
T-cell responses
• Efficient peptide-MHC-exchange based assay that allows cross-reactivity and safety studies for peptide-MHCantibodies and TCR mimics

Personalized NeoTCR-T Cell Therapies for Solid Tumors
ALEX FRANZUSOFF, CEO, PACT Pharma
PACT Pharma is developing personalized tumor-mutation (neoantigen or neoepitope) targeted T cells tailored for each patient. Using (non-viral) precision genome engineering, a fresh collection of autologous patient T cells are reprogrammed to produce ‘native’ autologous tumor mutation-targeted T cells (neoTCR-T cells) for administration as a ‘living drug’ back to the patient. In this talk, I will discuss PACT’s development of neoTCR-T cell products exclusively for each patient, as well as the remarkable landscape of neoE-specific T cells (direct capture) in blood or TILs of patients, as well as the evolution of neoE-T cell responses in I-O trials. These developments represent a new frontier for programming fresh, autologous human T cells with ‘new tricks’ to personalize the treatment of patients with the spectrum of solid tumors.

Profiling of neo-antigens presented by cancer cells facilitate patient stratification and development of potent antitumor therapies
TIM FUGMANN, Senior Scientist, Max Delbruck Center and Senior Scientific Advisor, Alithea Bio, Switzerland
• Aberrantly expressed transcripts lead to presentation of neo antigens on cancer cells
• Aberrant expression is a common event leading to antigens shared between multiple tumors
• Such neo antigens can be targeted by adoptive T cell therapies


Chair’s Closing Remarks / Conference Close


* 活动内容有可能不事先告知作更动及调整。

 

议程

本学会有超过350位专家齐聚一堂,对于如何将患者与成功可能性较高的治疗法做出连结进行讨论,对于致力研究开发因应个别患者状况提高治疗效果技术的学者来说,请千万不要错过本活动。

Download the Agenda (PDF)

演讲者

赞助商

所有赞助商名单

地点

London Heathrow Marriott Hotel

London Heathrow Marriott900

Bath Road, Harlington, Hayes, Middlesex, UB3 5AN

海报发表

海报发表不仅在休息时间进行,也会与分科会讨论同时进行。所有药厂或研究机构的研究人员所制作的海报,都必须在获得学会事务局许可后张贴于会场内指定区域。

此外,学会闭幕后,将发给所有出席者汇集海报发表大纲的电子书,亦可将海报以.pdf形式的档案公开(仅限意者)。

海报发表对于寻求出资和雇用机会的人,以及希望在志同道合、研究同一题目的研究者团体中发表成果的人来说,是能够在会场内广受矚目的珍贵机会。

必须报名参加本年会方可进行海报发表。张贴海报的空间有限,将依报名顺序接受通过审查者张贴海报,故建议尽早申请。

企业发表海报需要支付100英镑管理费用。费用包括区域保留费用与展示板费用以及各种其他手续费。研究机构与非营利组织可免费发表。

海报发表报名办法

请填写专用表格(点击下列连结下载)于2019年9月20日以前缴交。若于截止日期前额满将提早截止报名,敬请尽早申请。详情欢迎与我们联系。

学会的赞助商

赞助商募集

藉由成为本年会的赞助商或参展者,可在融洽的气氛中,与各组织的代表于各种正式、非正式的场合进行会谈,建立合作关系的机会。

本年会准备了各种赞助方案,丰富的选项可配合您的业务需求自由搭配,以获取最大额度的投资报酬。

欲采其他方式赞助本学会者,或考虑进行方案规画者,欢迎随时与本会洽询。本会将提出合乎个别需求的服务建议。

可事先预约的20分钟个别会谈时段

赞助商与参展者可以事先预约在主要研讨会的分科会会议中排定的20分钟个别会谈时段,与希望的对象见面。会期中,Global Engage团队会常驻会场,协助会谈按时进行。

年会前后的研讨会

可在年会前后以对特定主题感到兴趣者为对象,举办为期半天或全天的工作坊活动。Global Engage将协助宣传以确保工作坊达到足够的出席人数。

年会开幕前的行销与宣传

利用Global Engage的资料库展开行销活动,透过海报张贴、休息与午餐会、酒会、赞助海报发表等提高品牌知名度。另备有追加项目可将贵公司的logo印制在发放给与会者的名牌吊绳与年会资料包上。

参展

会议期间设有专用的展示区域,可向所有的与会者展示您的技术与产品。展示区域将设于休息及午餐会,以及第一天晚上的欢迎酒会的举办场所。

演讲

发言的型态

  • 30分钟演讲
  • 在30分钟专题讨论中担任主持人或讨论人员
  • 在年会议程中举行一小时的研讨会
募集赞助商

欢迎来信或来电与日商环球讯息有限公司台灣分公司联系。

包括签证等各种海关所需文件,以及展示用品的通关手续皆由展商企业各自负责。

展示相关的安排(企业介绍、公司商标、提供与会者目录中的展商资讯登录、展示空间的装潢、用品订购、展示用品的摆设搬运、展示空间的文件申请、保险等)请直接与主办方连系。

旅游相关疑问(住宿、机票)、当地翻译人员、飞行与意外保险等问题,将有另外的专门业者分别提供服务。

TMB & Neoantigen Congress赞助方案详情欢迎随时来信或来电询问

关于出席与各种方案详情欢迎随时询问。将有专员提供进一步资讯。

媒体合作伙伴

  • 247 Updates
  • Bentham Science
  • Biocompare
  • Biotechgate
  • EIN Presswire
  • Global Information
  • Pharma Journalist
  • PharmaVOICE
  • SciDoc Publishers
  • Pharmaceutical Tech
 
免费电子邮件通知服务